EUVIMEDEUVIMED entdecken
Crossref

Mutant Human Erythropoietin from Insect Cells as Novel Low Molecular‐Weight Internal Standards for ERAs Analysis

Chengshuai Niu iD, Junhan Mao, Sen He, Xinchao Liu, Xinmiao Zhou iD

Drug Testing and Analysis · 09.11.2026

DOI: 10.1002/dta.70187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Testing and Analysis, online erschienen am 09.11.2026. Verfasst von Chengshuai Niu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Anti-Doping Laboratory, Beijing Sport University, Beijing, China. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doping analysis of erythropoietin receptor agonists (ERAs) is frequently hindered by the “no band” phenomenon, in which endogenous erythropoietin (EPO) becomes undetectable owing to a variety of pre‐analytical factors. The absence of an internal standard (ISTD) poses the risk of an undetected sample preparation failure. Furthermore, the EPO gene variant c.577del presents a substantial analytical challenge. Specifically, the failure to identify variant‐encoded EPO (VAR‐EPO) during reverse immunopurification (RI) may cause false‐positive results for recombinant EPO (rEPO), highlighting the necessity of an ISTD for RI process monitoring. Nevertheless, the degradation of high molecular weight PEG‐modified ISTDs could interfere with ERAs detection. To address these technical limitations, low molecular weight ISTDs represent a superior alternative for methodological development. This study reports the strategic development of two novel low molecular weight ISTDs: a wild‐type EPO‐based designed mutant (INS1) and a mutant EPO encoded by the c.557del variant (INS2). Both mutant proteins were expressed in the H5 insect cell line via the baculovirus expression vector system. The two engineered EPO mutants possess simplified paucimannose‐type N‐glycans, conferring a distinctly lower molecular weight profile than endogenous EPO and mammalian cell‐expressed rEPO. Functionally, INS1 is designed to monitor the integrity of the initial testing procedure (ITP), whereas INS2 is engineered for process monitoring of RI to enable accurate rEPO confirmation. The results demonstrate that the developed low molecular weight ISTDs can effectively monitor procedural integrity and improve the detection performance of ERAs analytical assays.

Schlagwörter

Stichwörter der Autor:innen

baculovirus‐expression vector systemdoping analysiserythropoietin receptor agonistslow molecular weight internal standard

Autor:innen und Institutionen

  • Beijing Anti-Doping Laboratory, Beijing Sport University, Beijing, China.
  • School of Sport Science, Beijing Sport University, Beijing, China.

ORCID-Profile: Chengshuai Niu, Xinmiao Zhou

Zitieren

APA

Niu, C., Mao, J., He, S., Liu, X., & Zhou, X. (2026). Mutant Human Erythropoietin from Insect Cells as Novel Low Molecular‐Weight Internal Standards for ERAs Analysis. Drug Testing and Analysis. https://doi.org/10.1002/dta.70187

Vancouver

Niu C, Mao J, He S, Liu X, Zhou X. Mutant Human Erythropoietin from Insect Cells as Novel Low Molecular‐Weight Internal Standards for ERAs Analysis. Drug Testing and Analysis. 2026. doi:10.1002/dta.70187

BibTeX
@article{Niu2026,
  author = {Niu, Chengshuai and Mao, Junhan and He, Sen and Liu, Xinchao and Zhou, Xinmiao},
  title = {Mutant Human Erythropoietin from Insect Cells as Novel Low Molecular‐Weight Internal Standards for ERAs Analysis},
  journal = {Drug Testing and Analysis},
  year = {2026},
  doi = {10.1002/dta.70187}
}
Kostenlos starten →